@Article{Żołnierek2008,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="12",
number="7",
year="2008",
title="Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases",
abstract="  Background:  This single-centre retros-pective analysis of data from three randomized studies and two expanded-access studies compared the effect of interferon (IFN)-alpha, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC).    Material and methods:  In total, 292 patients were included in the analysis;  107 received sunitinib 50 mg/day in  6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received  placebo  or IFN-alpha 9 MU three times per week.    Results:  Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions during the study. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alpha at extending mean time to progression of pre-existing bone lesions (p=0.057). Compared with sorafenib, sunitinib significantly decreased formation (p=0.034) and prolonged time to occurrence of new bone lesions (p=0.047).    Conclusions:  Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.",
author="Żołnierek, Jakub
and Nurzyński, Paweł
and Langiewicz, Przemysław
and Oborska, Sylwia
and Waśko-Grabowska, Anna
and Kusztal, Ewa
and Obrocka, Beata
and Szczylik, Cezary",
pages="308--313",
url="https://www.termedia.pl/Efficacy-of-targeted-therapy-in-patients-with-renal-cell-carcinoma-with-pre-existing-or-new-bone-metastases,3,11345,1,1.html"
}